Arcutis Biotherapeutics, Inc. (ARQT) vs Arcus Biosciences, Inc. (RCUS)

Arcutis Biotherapeutics, Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Arcus Biosciences, Inc. are of similar size ($3.4B and $3.2B). Arcus Biosciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 122×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against −55.3%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −393.2%) and the higher return on invested capital (23.6% vs 0.00%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 12 and Arcus Biosciences, Inc. on 5.

Valuation

Metric ARQT RCUS Biotechnology median
P/E 122.36 n/m 7.88
P/S 7.57 26.65 11.47
P/B 15.93 6.72 2.52
Price to free cash flow 145.96 n/m 21.16
EV/EBITDA 95.16 n/m 0.74
EV/Sales 7.29 21.52 10.73
Earnings yield 0.82% (15.77%) (28.84%)
Free cash flow yield 0.69% (15.26%) (23.03%)

Profitability

Metric ARQT RCUS Biotechnology median
Gross margin 91.14% 100.00% 65.16%
Operating margin 7.38% (415.38%) 0.00%
Net margin 6.15% (393.16%) 0.00%
Free cash flow margin 8.42% (405.13%) 0.00%
Return on equity 15.86% (90.82%) (57.72%)
Return on assets 6.78% (46.02%) (49.22%)
Return on invested capital 23.62% 0.00% 0.00%

Growth

Metric ARQT RCUS Biotechnology median
Revenue growth (TTM) 76.11% (55.34%) 5.64%
EPS growth (last fiscal year) 88.79% (4.78%) —
Revenue growth, 5-year CAGR — 25.93% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARQT RCUS Biotechnology median
Debt to equity 0.49 0.22 0.00
Current ratio 2.92 3.82 4.73
Net debt to EBITDA 11.64 2.27 0.96

Dividend

Metric ARQT RCUS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARQT RCUS Biotechnology median
Market cap 3.39b 3.19b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack